sorafenib

Sorafenib is a protein kinase inhibitor with activity against many protein kinases, including VEGFR, PDGFR and RAF kinases.{{cite journal | vauthors = Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M | title = Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling | journal = Molecular Cancer Therapeutics | volume = 7 | issue = 10 | pages = 3129–3140 | date = October 2008 | pmid = 18852116 | doi = 10.1158/1535-7163.MCT-08-0013 | doi-access = free }} Of the RAF kinases, sorafenib is more selective for c-Raf than B-RAF.{{cite journal | vauthors = Smalley KS, Xiao M, Villanueva J, Nguyen TK, Flaherty KT, Letrero R, Van Belle P, Elder DE, Wang Y, Nathanson KL, Herlyn M | title = CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations | journal = Oncogene | volume = 28 | issue = 1 | pages = 85–94 | date = January 2009 | pmid = 18794803 | pmc = 2898184 | doi = 10.1038/onc.2008.362 }} (See BRAF (gene)#Sorafenib for details the drug's interaction with B-Raf.)

Sorafenib treatment induces autophagy,{{cite journal | vauthors = Zhang Y, Xue D, Wang X, Lu M, Gao B, Qiao X | title = Screening of kinase inhibitors targeting BRAF for regulating autophagy based on kinase pathways | journal = Molecular Medicine Reports | volume = 9 | issue = 1 | pages = 83–90 | date = January 2014 | pmid = 24213221 | doi = 10.3892/mmr.2013.1781 | doi-access = free }} which may suppress tumor growth. Based on its 1,3-disubstituted urea structure, sorafenib is also a potent soluble epoxide hydrolase inhibitor and this activity likely reduces the severity of its adverse effects.{{cite book | vauthors = Singh N, Hammock B | veditors = Offermanns S, Rosenthal W | title=Encyclopedia of Molecular Pharmacology | publisher=Springer, Cham |date=30 March 2020 | chapter=Soluble Epoxide Hydrolase |doi = 10.1007/978-3-030-21573-6 | hdl=10138/346042 | isbn=978-3-030-21573-6| s2cid=171511522 }}

Sorafenib is indicated as a treatment for advanced renal cell carcinoma (RCC), unresectable hepatocellular carcinomas (HCC) and thyroid cancer.{{cite web|title=Nexavar (sorafenib) dosing, indications, interactions, adverse effects, and more|work=Medscape Reference|publisher=WebMD|access-date=26 December 2013|url=http://reference.medscape.com/drug/nexavar-sorafenib-342260#showall|archive-date=27 December 2013|archive-url=https://web.archive.org/web/20131227052838/http://reference.medscape.com/drug/nexavar-sorafenib-342260#showall|url-status=live}}{{cite web|title=Nexavar (sorafenib) tablet, film coated [Bayer HealthCare Pharmaceuticals Inc.]|work=DailyMed|publisher=Bayer HealthCare Pharmaceuticals Inc.|date=November 2013|access-date=26 December 2013|url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b50667e4-5ebc-4968-a646-d605058dbef0|archive-date=20 September 2015|archive-url=https://web.archive.org/web/20150920064541/http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b50667e4-5ebc-4968-a646-d605058dbef0|url-status=live}}{{cite web|title=Nexavar 200mg film-coated tablets - Summary of Product Characteristics (SPC) - (eMC)|work=electronic Medicines Compendium|publisher=Bayer plc|date=27 March 2013|access-date=26 December 2013|url=http://www.medicines.org.uk/emc/medicine/18520/SPC/Nexavar+200mg+film-coated+tablets/|archive-date=27 December 2013|archive-url=https://web.archive.org/web/20131227025137/http://www.medicines.org.uk/emc/medicine/18520/SPC/Nexavar+200mg+film-coated+tablets/|url-status=live}}{{cite web|title=PRODUCT INFORMATION NEXAVAR (sorafenib tosylate)|work=TGA eBusiness Services|publisher=Bayer Australia Ltd|date=12 December 2012|access-date=26 December 2013|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-07403-3|format=PDF|archive-date=14 January 2016|archive-url=https://web.archive.org/web/20160114035221/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-07403-3|url-status=live}}

Clinical trial results, published January 2007, showed that, compared with placebo, treatment with sorafenib prolongs progression-free survival in patients with advanced clear cell renal cell carcinoma in whom previous therapy has failed. The median progression-free survival was 5.5 months in the sorafenib group and 2.8 months in the placebo group (hazard ratio for disease progression in the sorafenib group, 0.44; 95% confidence interval [CI], 0.35 to 0.55; P<0.01).{{cite journal | vauthors = Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM | title = Sorafenib in advanced clear-cell renal-cell carcinoma | journal = The New England Journal of Medicine | volume = 356 | issue = 2 | pages = 125–134 | date = January 2007 | pmid = 17215530 | doi = 10.1056/NEJMoa060655 | doi-access = free }}

In Australia this is one of two TGA-labelled indications for sorafenib, although it is not listed on the Pharmaceutical Benefits Scheme for this indication.

At ASCO 2007, results from the SHARP trial{{cite journal | vauthors = Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J | title = Sorafenib in advanced hepatocellular carcinoma | journal = The New England Journal of Medicine | volume = 359 | issue = 4 | pages = 378–390 | date = July 2008 | pmid = 18650514 | doi = 10.1056/NEJMoa0708857 | citeseerx = 10.1.1.531.1130 }} were presented, which showed efficacy of sorafenib in hepatocellular carcinoma. The primary endpoint was median overall survival, which showed a 44% improvement in patients who received sorafenib compared to placebo (hazard ratio 0.69; 95% CI, 0.55 to 0.87; p=0.0001). Both median survival and time to progression showed 3-month improvements; however, there was no significant difference in median time to symptomatic progression (p=0.77). There was no difference in quality of life measures, possibly attributable to toxicity of sorafenib or symptoms related to underlying progression of liver disease. Of note, this trial only included patients with Child-Pugh Class A (i.e. mildest) cirrhosis. Because of this trial sorafenib obtained FDA approval for the treatment of advanced hepatocellular carcinoma in November 2007.

In a randomized, double-blind, phase II trial combining sorafenib with doxorubicin, the median time to progression was not significantly delayed compared with doxorubicin alone in patients with advanced hepatocellular carcinoma. Median durations of overall survival and progression-free survival were significantly longer in patients receiving sorafenib plus doxorubicin than in those receiving doxorubicin alone.{{cite journal | vauthors = Keating GM, Santoro A | title = Sorafenib: a review of its use in advanced hepatocellular carcinoma | journal = Drugs | volume = 69 | issue = 2 | pages = 223–240 | year = 2009 | pmid = 19228077 | doi = 10.2165/00003495-200969020-00006 }}

A prospective single-centre phase II study which included the patients with unresectable hepatocellular carcinoma (HCC) concluding that the combination of sorafenib and DEB-TACE in patients with unresectable HCC is well tolerated and safe, with most toxicities related to sorafenib.{{cite journal | vauthors = Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF | title = Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma | journal = Journal of Clinical Oncology | volume = 29 | issue = 30 | pages = 3960–3967 | date = October 2011 | pmid = 21911714 | pmc = 4829081 | doi = 10.1200/JCO.2011.37.1021 }}

In Australia this is the only indication for which sorafenib is listed on the PBS and hence the only government-subsidised indication for sorafenib.{{cite web|title=Pharmaceutical Benefits Scheme (PBS) -SORAFENIB|work=Pharmaceutical Benefits Scheme|publisher=Australian Government Department of Health|access-date=27 December 2013|url=http://www.pbs.gov.au/medicine/item/9380Q|archive-date=27 December 2013|archive-url=https://web.archive.org/web/20131227071546/http://www.pbs.gov.au/medicine/item/9380Q|url-status=live}} Along with renal cell carcinoma, hepatocellular carcinoma is one of the TGA-labelled indications for sorafenib.

On 22 November 2013, sorafenib was approved by the FDA for the treatment of locally recurrent or metastatic, progressive differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment.{{cite web|url=http://www.cancer.gov/cancertopics/druginfo/fda-sorafenib-tosylate|title=FDA Approval for Sorafenib Tosylate|date=5 October 2006|website=National Cancer Institute|access-date=27 November 2013|archive-date=6 April 2015|archive-url=https://web.archive.org/web/20150406012049/http://www.cancer.gov/cancertopics/druginfo/fda-sorafenib-tosylate|url-status=live}}

The phase III DECISION trial showed significant improvement in progression-free survival but not in overall survival. However, as is known, the side effects were very frequent, specially hand and foot skin reaction.{{cite news|url=https://www.medpagetoday.com/meetingcoverage/asco/39545|title=ASCO: Sorafenib Halts Resistant Thyroid Cancer|date=4 June 2013|website=www.medpagetoday.com|access-date=21 December 2018|archive-date=23 March 2021|archive-url=https://web.archive.org/web/20210323215502/https://www.medpagetoday.com/MeetingCoverage/ASCO/39545|url-status=live}}

Adverse effects by frequency

Note: Potentially serious side effects are in bold.

Very common (>10% frequency)

{{div col|colwidth=18em}}

• Lymphopenia
• HypophosphataemiaLow blood phosphate levels
• HaemorrhageBleeding; including serious bleeds such as intracranial and intrapulmonary bleeds
• HypertensionHigh blood pressure
• Diarrhea
• Rash
• Alopecia (hair loss; occurs in roughly 30% of patients receiving sorafenib)
• Hand-foot syndrome
• Pruritus (itchiness)
• Erythema
• Increased amylase
• Increased lipase
• Fatigue
• PainIncluding abdominal pain, headache, tumour pain, etc.
• Nausea
• VomitingConsidered a low (~10-30%) risk chemotherapeutic agent for causing emesis){{cite web|title=Chemotherapy-Induced Nausea and Vomiting Treatment & Management|work=Medscape Reference|publisher=WebMD|date=3 July 2012|access-date=26 December 2013|url=http://emedicine.medscape.com/article/1355706-treatment#showall|archive-date=27 December 2013|archive-url=https://web.archive.org/web/20131227052153/http://emedicine.medscape.com/article/1355706-treatment#showall|url-status=live}}

{{div col end}}

Common (1-10% frequency)

{{div col|colwidth=18em}}

• LeucopeniaLow level of white blood cells in the blood
• NeutropoeniaLow level of neutrophils in the blood
• AnaemiaLow level of red blood cells in the blood
• ThrombocytopeniaLow level of plasma cells in the blood
• Anorexia (weight loss)
• HypocalcaemiaLow blood calcium
• HypokalaemiaLow blood potassium
• Depression
• Peripheral sensory neuropathy
• TinnitusHearing ringing in the ears
• Congestive heart failure
• Myocardial infarctionHeart attack
• Myocardial ischaemiaLack of blood supply for the heart muscle
• Hoarseness
• Constipation
• StomatitisMouth swelling, also dry mouth and glossodynia
• DyspepsiaIndigestion
• DysphagiaNot being able to swallow
• Dry skin
• Exfoliative dermatitis
• Acne
• Skin desquamation
• ArthralgiaSore joints
• MyalgiaMuscle aches
• Kidney failureKidney failure
• ProteinuriaExcreting protein [usually plasma proteins] in the urine. Not dangerous in itself but it is indicative kidney damage
• Erectile dysfunction
• Asthenia (weakness)
• Fever
• Influenza-like illness

{{div col end}}

• Transient increase in transaminase

Uncommon (0.1-1% frequency)

{{div col|colwidth=22em}}

• Folliculitis
• Infection
• Hypersensitivity reactionsIncluding skin reactions and urticaria (hives)
• HypothyroidismUnderactive thyroid
• HyperthyroidismOveractive thyroid
• HyponatraemiaLow blood sodium
• Dehydration
• Reversible posterior leukoencephalopathy
• Hypertensive crisis
• RhinorrhoeaRunny nose
• Interstitial lung disease-like eventsPneumonitis, radiation pneumonitis, acute respiratory distress, etc.
• Gastro-oesophageal reflux disease (GORD)
• PancreatitisSwelling of the pancreas
• GastritisSwelling of the stomach
• Gastrointestinal perforationsFormation of a hole in the gastrointestinal tract, leading to potentially fatal bleeds
• Increase in bilirubin leading, potentially, to jaundiceYellowing of the skin and eyes due to a failure of the liver to adequately cope with the amount of bilirubin produced by the day-to-day actions of the body
• CholecystitisSwelling of the gallbladder
• CholangitisSwelling of the bile duct
• Eczema
• Erythema multiformeA potentially fatal skin reaction
• KeratoacanthomaA fairly benign form of skin cancer
• Squamous cell carcinoma
• Gynaecomastia (swelling of the breast tissue in men)
• Transient increase in blood alkaline phosphatase
• INR abnormal
• Prothrombin level abnormal
• bulbous skin reaction{{cite journal| vauthors = Hagopian B |title=Unusually Severe Bullous Skin Reaction to Sorafenib: A Case Report|journal= Journal of Medical Cases|date=August 2010|volume=1|issue=1|pages=1–3|doi=10.4021/jmc112e|doi-access=free}}

{{div col end}}

Rare (0.01-0.1% frequency)

{{div col|colwidth=18em}}

• QT interval prolongationA potentially fatal abnormality in the electrical activity of the heart
• AngiooedemaSwelling of the skin and mucous membranes
• Anaphylactic reactionA potentially fatal allergic reaction
• HepatitisSwelling of the liver
• Radiation recall dermatitis
• Stevens–Johnson syndrome
• Leucocytoclastic vasculitis
• Toxic epidermal necrolysis
• Nephrotic syndrome
• RhabdomyolysisThe rapid breakdown of muscle tissue leading to the build-up of myoglobin in the blood and resulting in damage to the kidneys

{{div col end}}

Sorafenib was approved by the U.S. Food and Drug Administration (FDA) in December 2005,{{Cite web |url=http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/021923ltr.pdf |title=FDA Approval letter for use of sorafenib in advanced renal cancer |access-date=19 November 2009 |archive-date=30 March 2021 |archive-url=https://web.archive.org/web/20210330040359/https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/021923ltr.pdf |url-status=live }} and received European Commission marketing authorization in July 2006,{{cite web | publisher = European Commission | work = Enterprise and Industry. | url = http://ec.europa.eu/enterprise/pharmaceuticals/register/h342.htm | title = Nexavar | archive-url = https://web.archive.org/web/20080201001404/http://ec.europa.eu/enterprise/pharmaceuticals/register/h342.htm | archive-date = 1 February 2008 | access-date = 24 April 2007 }} both for use in the treatment of advanced renal cancer.

The European Commission granted marketing authorization to the drug for the treatment of patients with hepatocellular carcinoma(HCC), the most common form of liver cancer, in October 2007,{{cite press release|title=Nexavar (Sorafenib) Approved for Hepatocellular Carcinoma in Europe|url=http://www.pslgroup.com/news/content.nsf/medicalnews/852571020057CCF685257384005A45B1?OpenDocument&id=&count=10|publisher=Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals|date=30 October 2007|access-date=10 November 2012|url-status=dead|archive-url=https://web.archive.org/web/20120206215725/http://www.pslgroup.com/news/content.nsf/medicalnews/852571020057CCF685257384005A45B1?OpenDocument&id=&count=10|archive-date=6 February 2012}} and FDA approval for this indication followed in November 2007.{{Cite web |url=http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/021923s004,s005,s006,s007.pdf |title=FDA Approval letter for use of sorafenib in inoperable hepatocellular carcinoma |access-date=19 November 2009 |archive-date=31 March 2021 |archive-url=https://web.archive.org/web/20210331020338/https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/021923s004,s005,s006,s007.pdf |url-status=live }}

In November 2009, the UK's National Institute for Clinical Excellence declined to approve the drug for use within the NHS in England, Wales and Northern Ireland, stating that its effectiveness (increasing survival in primary liver cancer by 6 months) did not justify its high price, at up to £3000 per patient per month.{{cite web |url=http://news.bbc.co.uk/1/hi/health/8367614.stm |publisher=BBC News |title=Liver drug 'too expensive' |date=19 November 2009 |access-date=10 November 2012 |archive-date=11 September 2017 |archive-url=https://web.archive.org/web/20170911102550/http://news.bbc.co.uk/1/hi/health/8367614.stm |url-status=live }} In Scotland the drug had already been refused authorization by the Scottish Medicines Consortium for use within NHS Scotland, for the same reason.

In March 2012, the Indian Patent Office granted a domestic company, Natco Pharma, a license to manufacture generic sorafenib, bringing its price down by 97%. Bayer sells a month's supply, 120 tablets, of Nexavar for{{INRConvert|280000}}. Natco Pharma will sell 120 tablets for {{INRConvert|8800}}, while still paying a 6% royalty to Bayer. The royalty was later raised to 7% on appeal by Bayer.{{cite web |url=http://www.lawyerscollective.org/updates/supreme-court-says-no-to-bayer-upholds-compulsory-license-on-nexavar.html |url-status=dead |archive-url=https://web.archive.org/web/20150217113537/http://www.lawyerscollective.org/updates/supreme-court-says-no-to-bayer-upholds-compulsory-license-on-nexavar.html |archive-date=17 February 2015 |title=» Supreme Court says no to Bayer, upholds compulsory license on Nexavar}}{{cite web |url=http://www.ipindia.nic.in/ipoNew/compulsory_License_12032012.pdf |title=Application for Compulsory Licence Under Section 84(1) of the Patents Act, 1970 in Respect of Patent No.215758 | work = Controller of Patents Mumbai |access-date=2 April 2012 |url-status=dead |archive-url=https://web.archive.org/web/20120321173251/http://www.ipindia.nic.in/ipoNew/compulsory_License_12032012.pdf |archive-date=21 March 2012 }}{{cite journal |doi=10.1038/483250a |title = Indian generics | date = 9–15 March 2012 |journal=Nature |volume=483 |issue=7389 |pages=250–1|bibcode=2012Natur.483..250. |doi-access=free }} Under the Patents Act, 1970 and the World Trade Organisation TRIPS Agreement, the government can issue a compulsory license when a drug is not available at an affordable price.{{cite web|title=India Patents (Amendment) Act, 2005|url=http://www.wipo.int/wipolex/en/text.jsp?file_id=128116|publisher=WIPO|access-date=16 January 2013|archive-date=16 January 2013|archive-url=https://web.archive.org/web/20130116013515/http://www.wipo.int/wipolex/en/text.jsp?file_id=128116|url-status=live}}

In January 2014, Bayer's CEO Marijn Dekkers allegedly stated that Nexavar was developed for "Western patients who can afford it, not for Indians". A kidney cancer patient would pay $96,000 (£58,000) for a year's course of the Bayer-made drug, whereas the cost of the Indian version of the generic drug would be around $2,800 (£1,700).{{Cite web | url=https://archives.cjr.org/the_audit/bloombergs_viral_misquote_1.php | vauthors = Chittum R | date = 29 January 2014 | work = Columbia Journalism Review | title=Bloomberg's viral misquote | access-date=12 September 2019 | archive-date=10 February 2021 | archive-url=https://web.archive.org/web/20210210092049/https://archives.cjr.org/the_audit/bloombergs_viral_misquote_1.php | url-status=live }}

In some kinds of lung cancer (with squamous-cell histology) sorafenib administered in addition to paclitaxel and carboplatin may be detrimental to patients.{{cite web | vauthors = Chustecka Z | date = April 25, 2008 |url=http://www.medscape.com/viewarticle/573511|title=Addition of Sorafenib May Be Detrimental in Some Lung Cancer Patients| work = MedScape |access-date=29 October 2010|archive-date=29 August 2021|archive-url=https://web.archive.org/web/20210829064212/https://www.medscape.com/viewarticle/573511|url-status=live}}

Sorafenib has been studied as maintenance therapy after ovarian cancer treatment and in combination with chemotherapy for recurrent ovarian cancer but did not show results that led to approval of the drug for these indications.{{cite journal | vauthors = Ciccone MA, Maoz A, Casabar JK, Machida H, Mabuchi S, Matsuo K | title = Clinical outcome of treatment with serine-threonine kinase inhibitors in recurrent epithelial ovarian cancer: a systematic review of literature | journal = Expert Opinion on Investigational Drugs | volume = 25 | issue = 7 | pages = 781–796 | date = July 2016 | pmid = 27101098 | pmc = 7534810 | doi = 10.1080/13543784.2016.1181748 | s2cid = 28717797 }}

There is a phase I/II study at the Mayo Clinic{{ClinicalTrialsGov|NCT00329719|Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma}} of sorafenib and CCI-779 (temsirolimus) for recurrent glioblastoma.

A study performed in 2008 showed that sorafenib is active against aggressive fibromatosis. This study is being used as justification for using sorafenib as an initial course of treatment in some patients with the condition.{{cite journal | vauthors = Gounder MM, Lefkowitz RA, Keohan ML, D'Adamo DR, Hameed M, Antonescu CR, Singer S, Stout K, Ahn L, Maki RG | title = Activity of Sorafenib against desmoid tumor/deep fibromatosis | journal = Clinical Cancer Research | volume = 17 | issue = 12 | pages = 4082–4090 | date = June 2011 | pmid = 21447727 | pmc = 3152981 | doi = 10.1158/1078-0432.CCR-10-3322 }}

A phase III clinical trial is testing the effectiveness of sorafenib to treat desmoid tumors (also known as aggressive fibromatosis), after positive results in the first two trial stages. Dosage is typically half of that applied for malignant cancers (400 mg vs 800 mg). NCI are sponsoring this trial.{{cite web|title=Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis|url=http://clinicaltrials.gov/show/NCT02066181|website=Clinicaltrials.gov|access-date=12 November 2014|archive-date=13 November 2014|archive-url=https://web.archive.org/web/20141113012518/http://clinicaltrials.gov/show/NCT02066181|url-status=live}}{{cite journal | vauthors = Gounder MM, Lefkowitz RA, Keohan ML, D'Adamo DR, Hameed M, Antonescu CR, Singer S, Stout K, Ahn L, Maki RG | title = Activity of Sorafenib against desmoid tumor/deep fibromatosis | journal = Clinical Cancer Research | volume = 17 | issue = 12 | pages = 4082–4090 | date = June 2011 | pmid = 21447727 | pmc = 3152981 | doi = 10.1158/1078-0432.ccr-10-3322 }}{{cite journal | vauthors = Mangla A, Agarwal N, Schwartz G | title = Desmoid Tumors: Current Perspective and Treatment | journal = Current Treatment Options in Oncology | volume = 25 | issue = 2 | pages = 161–175 | date = February 2024 | pmid = 38270798 | pmc = 10873447 | doi = 10.1007/s11864-024-01177-5 | doi-access = free }}

• Donafenib, a deuterated derivative of sorafenib with improved pharmacokinetic properties

{{reflist|group = Note}}

{{reflist}}

• {{cite web | url = https://druginfo.nlm.nih.gov/drugportal/name/sorafenib | publisher = U.S. National Library of Medicine | work = Drug Information Portal | title = Sorafenib }}
• {{cite web | title=Sorafenib | website=National Cancer Institute | url=https://www.cancer.gov/publications/dictionaries/cancer-drug/def/sorafenib-tosylate }}
• {{ClinicalTrialsGov|NCT00217399|Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer}}

{{Extracellular chemotherapeutic agents}}

{{Cytokine receptor modulators}}

{{Growth factor receptor modulators}}

{{Portal bar | Medicine}}

Category:Drugs developed by Bayer

Category:Orphan drugs

Category:Receptor tyrosine kinase inhibitors

Category:Chloroarenes

Category:Trifluoromethyl compounds

Category:Anilines

Category:Ureas

Category:Phenol ethers

Category:Pyridines

Category:Carboxamides

Category:Diaryl ethers